6489 LOGO20THELANSIS 33

The incidence cases of PCED in the US is

Read more:- Persistent Corneal Epithelial Defect (PCED) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 

Persistent-Corneal-Epithelial-Defect-PCED-forecast

 

Comprehensive insight on patient segmentation based on age, sex, Settings (Acute & Refractory cases), Risk factors (Ocular herpes sim-plex, epithelial and stromal keratitis, scarring, tissue destruction, neovascularization, and glaucoma) Signs & Symptoms, etiology (defective epithelial adhesion, limbal stem cell deficiency, surface trauma, medications, infections, and other ) Clinical Manifestations, Treatment types (Aggressive lubrication, Punctal occlusion, Bandage soft contact lens, Pressure patching, Amniotic membrane grafting, Autologous serum, Scleral contact lenses, Topical and systemic antibiotics, anti-inflammatory agents and Others) has been provided into the epidemiology section of the PCED and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

 

CI IMAGE

 

In terms of pharmacologic therapies, there are few drug candidates/biologicals are in different Phase (Phase I, II & III) stages of development. Key companies are Kala Pharmaceuticals, Noveome Biotherapeutics, Santen Pharmaceutical, OcuNexus Therapeutics, Zhaoke Ophthalmology Pharmaceutical Ltd. And Eyevance Pharmaceuticals. Autologous adipose-derived mesenchymal stem cells (MSCs) have recently been introduced as a potential breakthrough therapy for PED and stromal ulceration. These cells are multipotent and therefore have the capacity to differentiate into any human cell type. Thymosin beta 4 is a synthetically produced copy of a 43-amino acid peptide that has been demonstrated to promote corneal wound re-epithelialization, diminish inflammation, and inhibit apoptosis. Looking at the current clinical development and assets progress card, it would really be a great opportunity for the pharmaceutical company to build products around the treatment of PCED specifically for refractory patients.

 

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

 

Other Reports:-
X-linked hypophosphatemia (XLH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Relapsed and refractory multiple myeloma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Chronic Venous Insufficiency (CVI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Ornithine Transcarbamylase (OTC) Deficiency – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Respiratory syncytial virus (RSV) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: Persistent Corneal Epithelial Defect (PCED) market outlook report, Persistent Corneal Epithelial Defect (PCED) competitive landscape, Persistent Corneal Epithelial Defect (PCED), Persistent Corneal Epithelial Defect (PCED) market forecast